Search for a command to run...
The proposed project will combine and standardize data from the placebo groups of several Phase 3 clinical trials focused on Alzheimer’s disease (AD), a progressive brain disorder that affects memory, thinking, and behavior. These efforts will involve working with two types of standardized datasets commonly used in clinical research: Study Data Tabulation Model (SDTM) files, which organize raw clinical trial data, and Analysis Data Model (ADaM) files, which are prepared to support statistical analysis. Both formats are used to meet U.S. Food and Drug Administration (FDA) requirements for data submission. The project will include harmonizing—or aligning—the structure and content of these datasets by standardizing variables such as demographic information and disease-specific measurements. The end goal is to make the data from different studies stackable, meaning they can be merged into a single, consistent file. This makes it easier for approved researchers to analyze the data as one dataset, rather than working with separate files from each study. The resulting harmonized dataset, which includes only placebo-arm data, will be made available to qualified researchers participating in an upcoming data challenge. A data challenge sponsored by the AD Data Initiative will be run to help further research being done in the Alzheimer's space. Our goal is to harmonize the data to allow it to be as user friendly as possible for researchers as they explore different routes of researching the disease space. The data challenge will be open ended with researchers being given the opportunity to explore the data as they see fit and beneficial. After standardization, the data will be made requestable to all those participating in the data challenge. The governance for making the harmonized data available would be governed by the IRP. Data Contributor review would be skipped in this instance as the preferred approach. The findings and results from the data challenge will be published according to the publication requirements outlined in the Data Use Agreements. We believe this shared resource will be a valuable tool for advancing Alzheimer’s and related dementias (ADRD) research, helping scientists conduct more efficient, powerful analyses that can lead to new insights and discoveries.